FGL
Synthetic NCAM-mimetic peptide that binds FGFR1 and promotes neuroplasticity; in rats it enhanced spatial learning/memory and hippocampal LTP.
4 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
FGL (L) is a compound studied only in animals and lab experiments so far. Synthetic NCAM-mimetic peptide that binds FGFR1 and promotes neuroplasticity; in rats it enhanced spatial learning/memory and hippocampal LTP.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsSystemic s.c. injection in adult rats (dose not in abstracts); local intracerebral injection in anesthetized rats; in vitro neural stem cell concentrationsCommunity-reportedCommunity-reported: 1–2 mg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It mimics a nerve-cell adhesion protein and strengthened brain-cell signaling in rat studies. Proposed mechanism, from rat studies: an NCAM-derived mimetic peptide. In rat hippocampus it enhanced synaptic transmission by facilitating synaptic delivery of AMPA receptors, with enhanced long-term potentiation (Knafo 2012); in aged rats it attenuated markers of microglial activation (Downer 2010).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported doses of 1–2 mg (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| FGL (L) | Unknown | Subcutaneous injection | Preclinical (animal) |
| Dihexa | Unknown | Oral or intraperitoneal (rodent studies only); no human administration published | Preclinical (animal) |
| P21 | Unknown | Oral (mice) | Preclinical (animal) |
| PE-22-28 | No published PK data found | Subcutaneous injection, Intranasal | Preclinical (animal) |
| Pinealon | No published PK data found | Oral, Sublingual | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Cognitive category. View All Cognitive Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.